SynthesisClinical cardiology2022
Characteristics and long-term prognosis of patients with reduced, mid-range, and preserved ejection fraction: A systemic review and meta-analysis.
Synthesis in Clinical cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Glucose cotransporter-2 inhibitors on mortality and hospitalization in heart failure patients: a comprehensive meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Epidemiology of heart failure in diabetes: a disease in disguise.Diabetologia · 2024Pooled it
- Characteristics and long-term prognosis of patients with reduced, mid-range, and preserved ejection fraction: A systemic review and meta-analysis.Clinical cardiology · 2022Pooled it
- Two Phenotypes, One Prognosis: Period-Specific Mortality and Prediction of Post-Discharge Events in Acute Heart Failure.Journal of cardiovascular development and disease · 2026Article
- Mortality in Patients With Hodgkin Lymphoma and Heart Failure: A Swedish Population-Based Study.JACC. Advances · 2026Article
- Postoperative Complications in Patients With Heart Failure With Reduced vs Preserved Ejection Fraction Undergoing Total Hip and Knee Arthroplasty.Arthroplasty today · 2026Article
- Characteristics and outcomes of patients with heart failure and reduced left ventricular ejection fraction in relation to sodium-glucose cotransporter-2 inhibitor treatment: real-world data from the multicentre HClinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Predicting ICU admission in geriatric hip fracture patients with heart failure: the role of O-POSSUM and heart failure subtypes.BMC geriatrics · 2026Article
- Nonlinear association of HbA1c/HDL-C ratio with heart failure in adults: a large cross-sectional study.Frontiers in cardiovascular medicine · 2026Article
- The C-reactive protein-to-body mass index ratio predicts prognosis in patients with different types of heart failure.Open medicine (Warsaw, Poland) · 2026Article
- Initiation of SGLT2 inhibitors versus mineralocorticoid receptor antagonists as third-line therapy in heart failure with reduced ejection fraction: a nationwide cohort study.The Lancet regional health. Europe · 2026Article
- Heart Failure in Lebanon: A Glimpse into the Reality of Growing Burden.Diagnostics (Basel, Switzerland) · 2025Article
- Impact of diabetes and ejection fraction on non-ST-Segment elevation myocardial infarction outcomes.Heart and vessels · 2025Article
- Improvement in Right Ventricular Function and Pulmonary Pressures in Patients With Severe Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction Treated With Sacubitril-Valsartan.Pulmonary circulation · 2025Article
- Article
- Revisiting Abnormalities of Ventricular Depolarization: Redefining Phenotypes and Associated Outcomes Using Tree-Based Dimensionality Reduction.Journal of the American Heart Association · 2025Article
- Historical Redlining and Cardio-Kidney-Metabolic Disease Risk Factors, Prevalence, and Outcomes: A Scoping Review.JACC. Advances · 2025Article
- Machine Learning-Based Risk Factor Analysis and Prediction Model Construction for the Occurrence of Chronic Heart Failure: Health Ecologic Study.JMIR medical informatics · 2025Article
- Diagnosis and Management of Hypertensive Heart Disease: Incorporating 2023 European Society of Hypertension and 2024 European Society of Cardiology Guideline Updates.Journal of cardiovascular development and disease · 2025Review
- Long-Term Prognostic Impact of Three-Dimensional Speckle-Tracking Echocardiography-Derived Left Ventricular Global Longitudinal Strain in Healthy Adults-Insights from the MAGYAR-Healthy Study.Journal of cardiovascular development and disease · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsPatients with heart failure (HF) have a poor prognosis and are categorized by ejection fraction. We performed a meta-analysis to compare baseline characteristics and long-term outcomes of patients with heart failure with reduced (HFrEF), mid-range (HFmrEF), and preserved ejection fraction (HFpEF). METHODS AND
resultsA total of 27 prospective studies were included. Patients with HFpEF were older and had a higher proportion of females, hypertension, diabetes, and insufficient neuroendocrine antagonist treatments, while patients with HFrEF and HFmrEF had a higher prevalence of coronary heart disease and chronic kidney disease. After more than 1-year of follow-up, all-cause mortality was significantly lower in patients with HFmrEF 9388/25 042 (37.49%) than those with HFrEF 39 333/90 023 (43.69%) and HFpEF 24 828/52 492 (47.30%) (p < .001). Cardiovascular mortality was lowest in patients with HFpEF 1130/9904 (11.41%), highest in patients with HFrEF 3419/16 277 (21.07%) mainly coming from HF death and sudden cardiac death, and middle in patients with HFmrEF 699/5171 (13.52%) and the non-cardiovascular mortality was on the contrary. Subgroup analysis showed that in high-risk patients with atrial fibrillation, the all-cause mortality of HFpEF was significantly higher than both HFrEF and HFmrEF (p < .001). HF hospitalization was lowest in patients with HFmrEF 1822/5285 (34.47%), highest in patients with HFrEF 12 607/28 590 (44.10%) and middle in patients with HFpEF 8686/22 763 (38.16%) and the composite of all-cause mortality and HF hospitalization was also observed similar results.
conclusionsIn summary, patients with HFmrEF had the lowest incidence of all-cause mortality and HF hospitalization, while the highest all-cause mortality and HF hospitalization rates were HFpEF and HFrEF patients, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.